Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network.

Author(s)
Murad, Yousif
Hung, Te-Yu
Sadarangani, Manish
Morris, Shaun K
Le Saux, Nicole
Vanderkooi, Otto G
Kellner, James D
Tyrrell, Gregory J
Martin, Irene
Demczuk, Walter
Halperin, Scott A
Bettinger, Julie A
Bridger, N
Foo, Cheryl
Halperin, S A
Top, K A
Thibeault, R
Moore, D
Papenburg, J
Lebel, M
Le Saux, N
Morris, S
Embree, J
Tan, B
McConnell, Athena
Jadavji, T
Constantinescu, C
Vaudry, W
Scheifele, D
Sadarangani, M
Bettinger, J
Sauvé, L
Publication Date
2022-04-01
Abstract
BACKGROUND: Invasive pneumococcal disease due to Streptococcus pneumoniae can cause mortality and severe morbidity due to sepsis, meningitis and pneumonia, particularly in young children and the elderly. Recurrent invasive pneumococcal disease is rare yet serious sequelae of invasive pneumococcal disease that is associated with the immunocompromised and leads to a high mortality rate. METHOD: This retrospective study reviewed recurrent invasive pneumococcal disease cases from the Canadian Immunization Monitoring Program, ACTive (IMPACT) between 1991 and 2019, an active network for surveillance of vaccine-preventable diseases and adverse events following immunization for children ages 0-16 years. Data were collected from 12 pediatric tertiary care hospitals across all 3 eras of public pneumococcal conjugate vaccine implementation in Canada. RESULTS: The survival rate within our cohort of 180 recurrent invasive pneumococcal disease cases was 98.3%. A decrease of 26.4% in recurrent invasive pneumococcal disease due to vaccine serotypes was observed with pneumococcal vaccine introduction. There was also a 69.0% increase in the rate of vaccination in children with preexisting medical conditions compared with their healthy peers. CONCLUSION: The decrease in recurrent invasive pneumococcal disease due to vaccine-covered serotypes has been offset by an increase of non-vaccine serotypes in this sample of Canadian children.
Affiliation
From the Faculty of Medicine, University of British Columbia, Vancouver, Canada.
Vaccine Evaluation Center, BC Children's Hospital Research Institute, Vancouver, Canada.
(Hung TY) Royal Darwin Hospital, Top End Health Service, Northern Territory, Australia.
Royal Melbourne Hospital, Doherty Institute for Infection Immunity, Victoria, Australia.
Department of Pediatrics, University of British Columbia, Vancouver, Canada.
Division of Infectious Diseases, Hospital for Sick Children, Toronto, Canada.
Department of Pediatrics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
Children's Hospital of Eastern Ontario, Paediatric Infectious Disease, Ottawa, ON, Canada.
Departments of Microbiology, Immunology and Infectious Diseases, Pathology & Laboratory Medicine and Community Health Sciences, Alberta Children's Hospital, Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.
Department of Pediatrics, University of Calgary, Calgary, AB, Canada.
Division of Diagnostic and Applied Microbiology, Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Canada.
Alberta Precision Laboratories-Public Health, Edmonton, Canada.
National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Canada.
Canadian Center for Vaccinology, Dalhousie University, IWK Health, and Nova Scotia Health, Halifax, Canada.
Janeway Children's Health & Rehabilitation Centre, St. John's, NL.
IWK Health Centre, Halifax, NS.
Centre Mère-Enfant de Québec, CHUL, Quebec City, PQ.
The Montreal Children's Hospital, Montreal, PQ.
CHU Ste-Justine, Montreal, PQ.
Children's Hospital of Eastern Ontario, Ottawa, ON.
The Hospital for Sick Children, Toronto, ON.
Winnipeg Children's Hospital, Winnipeg, MB.
Jim Pattison Children's Hospital, Saskatoon, SK.
Alberta Children's Hospital, Calgary, AB.
Stollery Children's Hospital, Edmonton, AB.
BC Children's Hospital, Vancouver, BC.
Citation
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Pediatr Infect Dis J. 2022 Apr 1;41(4):e166-e171. doi: 10.1097/INF.0000000000003454.
Pubmed ID
https://pubmed.ncbi.nlm.nih.gov/35093996/?otool=iaurydwlib
Link
Volume
41
Title
Clinical Presentations and Outcomes of Children in Canada With Recurrent Invasive Pneumococcal Disease From the IMPACT Surveillance Network.
Type of document
Journal Article
Entity Type
Publication

Files:

NameSizeformatDescriptionLink
https://digitallibrary.health.nt.gov.au/nthealthserver/api/core/items/fd78972b-c8f8-438f-aa6b-f80f8cb05507